Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-577-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees75
Next Earnings Date11/7/2019 (Estimated)
OptionableNot Optionable
Evelo Biosciences (NASDAQ:EVLO) Frequently Asked Questions
What is Evelo Biosciences' stock symbol?
Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."
How were Evelo Biosciences' earnings last quarter?
Evelo Biosciences Inc (NASDAQ:EVLO) posted its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.60) by $0.05. View Evelo Biosciences' Earnings History.
When is Evelo Biosciences' next earnings date?
What price target have analysts set for EVLO?
4 equities research analysts have issued twelve-month price objectives for Evelo Biosciences' stock. Their forecasts range from $10.00 to $25.00. On average, they expect Evelo Biosciences' stock price to reach $17.67 in the next year. This suggests a possible upside of 170.5% from the stock's current price. View Analyst Price Targets for Evelo Biosciences.
What is the consensus analysts' recommendation for Evelo Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evelo Biosciences.
What are Wall Street analysts saying about Evelo Biosciences stock?
Here are some recent quotes from research analysts about Evelo Biosciences stock:
- 1. According to Zacks Investment Research, "Evelo Biosciences, Inc. operates as a bio-technology company. It develops therapies for the treatment of the gut-body network. The company also offers treatment for cancer and inflammatory diseases. Its product portfolio consists of EDP1066 which are in clinical stage. Evelo Biosciences is based in Massachusetts, United States. " (8/10/2019)
- 2. Chardan Capital analysts commented, "We have previously expressed some concern on the robustness of this mechanism based on cell trafficking numbers in preclinical animal models (see our 29 January 2019 initiation). The new formulation announced today, though, increases potency up to 30-fold in animal studies, according to management, which could substantially enhance the efficacy signals seen in the clinical trials. The change in formulation, we understand, alters the kinetics of delivery and target engagement relative to the initial product." (5/2/2019)
Has Evelo Biosciences been receiving favorable news coverage?
Media coverage about EVLO stock has trended somewhat negative on Saturday, according to InfoTrie. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Evelo Biosciences earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Evelo Biosciences.
Are investors shorting Evelo Biosciences?
Evelo Biosciences saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 2,040,000 shares, an increase of 13.3% from the August 30th total of 1,800,000 shares. Based on an average daily volume of 59,100 shares, the short-interest ratio is currently 34.5 days. Approximately 19.3% of the shares of the company are short sold. View Evelo Biosciences' Current Options Chain.
Who are some of Evelo Biosciences' key competitors?
Some companies that are related to Evelo Biosciences include Dova Pharmaceuticals (DOVA), Athenex (ATNX), Omeros (OMER), G1 Therapeutics (GTHX), CannTrust (CNTTF), Cara Therapeutics (CARA), Principia Biopharma (PRNB), Axsome Therapeutics (AXSM), Vanda Pharmaceuticals (VNDA), Rhythm Pharmaceuticals (RYTM), Organogenesis (ORGO), Stoke Therapeutics (STOK), Wave Life Sciences (WVE), Kura Oncology (KURA) and Emisphere Technologies (EMIS).
What other stocks do shareholders of Evelo Biosciences own?
Who are Evelo Biosciences' key executives?
Evelo Biosciences' management team includes the folowing people:
- Dr. Noubar B. Afeyan Ph.D., Co-founder & Chairman (Age 56)
- Dr. Balkrishan Gill, Pres, CEO & Director (Age 54)
- Dr. Mark Bodmer, Chief Scientific Officer and Pres of R&D (Age 61)
- Dr. Duncan McHale M.D., Ph.D., Chief Medical Officer (Age 52)
- Mr. Jonathan Poole, CFO & Treasurer (Age 44)
When did Evelo Biosciences IPO?
(EVLO) raised $85 million in an initial public offering (IPO) on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.
How do I buy shares of Evelo Biosciences?
Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Evelo Biosciences' stock price today?
One share of EVLO stock can currently be purchased for approximately $6.53.
How big of a company is Evelo Biosciences?
Evelo Biosciences has a market capitalization of $209.35 million. The company earns $-56,940,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Evelo Biosciences employs 75 workers across the globe.View Additional Information About Evelo Biosciences.
What is Evelo Biosciences' official website?
How can I contact Evelo Biosciences?
Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company can be reached via phone at 617-577-0300 or via email at [email protected]
MarketBeat Community Rating for Evelo Biosciences (NASDAQ EVLO)
MarketBeat's community ratings are surveys of what our community members think about Evelo Biosciences and other stocks. Vote "Outperform" if you believe EVLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
